Physicians Financial Services Inc. continued to hold its position in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,863 shares of the life sciences company’s stock at the end of the second quarter. Physicians Financial Services Inc.’s holdings in Illumina were worth $497,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. First Citizens Bank & Trust Co. raised its stake in Illumina by 0.4% in the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock worth $536,000 after buying an additional 12 shares during the last quarter. Patten Group Inc. raised its stake in Illumina by 2.7% in the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the last quarter. Puzo Michael J raised its stake in Illumina by 0.4% in the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock worth $1,032,000 after buying an additional 25 shares during the last quarter. Forte Capital LLC ADV raised its stake in Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock worth $373,000 after buying an additional 35 shares during the last quarter. Finally, Gemmer Asset Management LLC raised its stake in Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock worth $117,000 after buying an additional 37 shares during the last quarter. Institutional investors and hedge funds own 93.81% of the company’s stock.

Illumina, Inc. (NASDAQ:ILMN) opened at 194.47 on Monday. The firm’s 50-day moving average is $174.66 and its 200 day moving average is $171.89. Illumina, Inc. has a 12-month low of $119.37 and a 12-month high of $198.55. The stock has a market capitalization of $28.39 billion, a P/E ratio of 39.02 and a beta of 0.83.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business had revenue of $662 million for the quarter, compared to analysts’ expectations of $642.38 million. During the same period in the prior year, the company posted $0.86 EPS. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities analysts expect that Illumina, Inc. will post $3.65 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Physicians Financial Services Inc. Maintains Stake in Illumina, Inc. (NASDAQ:ILMN)” was first reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/08/07/physicians-financial-services-inc-maintains-stake-in-illumina-inc-nasdaqilmn.html.

A number of analysts have recently weighed in on ILMN shares. Bank of America Corporation increased their price objective on shares of Illumina from $175.00 to $195.00 and gave the stock a “buy” rating in a research note on Tuesday, April 11th. Vetr lowered shares of Illumina from a “strong-buy” rating to a “buy” rating and set a $193.40 price objective on the stock. in a research note on Tuesday, April 11th. Zacks Investment Research lowered shares of Illumina from a “buy” rating to a “hold” rating in a research note on Thursday, April 13th. Piper Jaffray Companies reiterated an “overweight” rating and issued a $187.00 price objective (up previously from $170.00) on shares of Illumina in a research note on Friday, April 14th. Finally, Cantor Fitzgerald increased their price objective on shares of Illumina from $155.00 to $170.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 26th. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $174.38.

In other news, Director Jay T. Flatley sold 20,000 shares of the company’s stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $176.43, for a total transaction of $3,528,600.00. Following the transaction, the director now directly owns 534,176 shares of the company’s stock, valued at approximately $94,244,671.68. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Jay T. Flatley sold 15,000 shares of the company’s stock in a transaction on Tuesday, May 23rd. The stock was sold at an average price of $175.53, for a total transaction of $2,632,950.00. Following the transaction, the director now directly owns 534,176 shares in the company, valued at $93,763,913.28. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 156,770 shares of company stock worth $28,069,728. Corporate insiders own 1.60% of the company’s stock.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.